^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Valcyte (valganciclovir)

    i
    Other names: RS-079070194, RS-79070, TA 9070, RO1079070/194, RS079070194, RS79070, TA9070, R127, RG127, TA-9070, RG 127, RO 1079070/194, RS 079070194, RS 79070, RO-1079070/194
    Associations

    News

    Trials
    Company:
    Roche, Tanabe Pharma
    Drug class:
    Cytomegalovirus replication inhibitor
    Associations

    News

    Trials
    5d
    CLEAR-CMV: Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients (clinicaltrials.gov)
    P4, N=40, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Valcyte (valganciclovir)
    12d
    Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma. (PubMed, Clin J Gastroenterol)
    Valganciclovir was initiated, and prednisolone was discontinued. Although irAE gastritis is a rare complication of ICI therapy, it should be considered in patients presenting with upper gastrointestinal symptoms during treatment. The management of irAE gastritis requires vigilance for opportunistic infections, timely histopathological evaluation, and careful differentiation from viral infections, especially in cases refractory to corticosteroids.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Valcyte (valganciclovir)
    12d
    Unmasking Cytomegalovirus Colitis: A Case of Haemorrhagic Colitis in a Patient with Chronic Myeloid Leukaemia on Dasatinib. (PubMed, Eur J Case Rep Intern Med)
    In immunosuppressed patients being treated with dasatinib, haemorrhagic colitis can mask an underlying infection.Tissue biopsy constitutes a key tool for promptly diagnosing cytomegalovirus colitis, enabling clinicians to start treatment early and thus prevent adverse outcomes.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    dasatinib • Valcyte (valganciclovir)
    12d
    STACCATO: Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes (clinicaltrials.gov)
    P2/3, N=51, Terminated, University of California, San Francisco | Completed --> Terminated; Funding discontinued.
    Trial termination
    |
    Valcyte (valganciclovir)
    19d
    Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, The Methodist Hospital Research Institute
    New P2 trial
    |
    Valcyte (valganciclovir)
    22d
    NIRVANA: ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Wits Health Consortium (Pty) Ltd
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Valcyte (valganciclovir)
    25d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    1m
    Beyond the Watershed: Chronic Ischemic Colitis Masking Underlying Small Bowel Non-Hodgkin Lymphoma. (PubMed, Cureus)
    She required intensive care with vasopressors and mechanical ventilation and was treated for cytomegalovirus viremia with intravenous ganciclovir followed by valganciclovir. Primary intestinal lymphoma can mimic IC through obstruction and microvascular compromise. Early recognition of atypical right-sided IC is essential, as prompt surgery and biopsy can identify underlying malignancy and guide timely oncologic management.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    Valcyte (valganciclovir)
    2ms
    De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Virginia Commonwealth University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    Valcyte (valganciclovir)
    2ms
    VIGAS2: A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients (clinicaltrials.gov)
    P2, N=220, Active, not recruiting, Cecilia Soderberg-Naucler | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Valcyte (valganciclovir)
    2ms
    Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, National Taiwan University Hospital
    New trial • Head-to-Head
    |
    Valcyte (valganciclovir) • valacyclovir
    3ms
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=124 --> 37
    Enrollment closed • Enrollment change
    |
    GEN2 • Valcyte (valganciclovir)